Literature DB >> 6427480

Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate.

G M Preminger, C L Knupp, J P Hindsley, J M Jenkins, F A Fried, P M Blatt.   

Abstract

Anti-factor VIII antibodies, inherited or acquired inhibitors of the factor VIII molecule, have not been reported previously in the urological literature. Although more common in hemophiliac patients who have received multiple transfusions, this anticoagulant may be the cause of severe hemorrhage in nonhemophiliac patients. We describe a patient with carcinoma of the prostate and an unsuspected anti-factor VIII antibody, who experienced excessive postoperative bleeding and prolonged hospitalization following a vesicolithotomy and bilateral orchiectomy. A prolonged partial thromboplastin time and a significant decrease in measurable factor VIII clotting activity in a patient with no history of bleeding problems are essential clues in making the diagnosis of a factor VIII inhibitor. This coagulation defect is treated best with prothrombin complex concentrates, which contain vitamin K dependent clotting factors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427480     DOI: 10.1016/s0022-5347(17)50864-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  [Prostate carcinoma associated spontaneous factor VIII:C inhibitor hemophilia. Successful therapy of severe hemorrhagic complication with porcine factor VIII in a 75-year-old patient].

Authors:  T Orth; M Schnütgen; W Herr; W J Mayet; W Dippold; R Wanitschke; K H Meyer zum Buschenfelde
Journal:  Med Klin (Munich)       Date:  1997-04-15

2.  Failure of fresh frozen plasma infusion and vitamin K to correct elevated international normalised ratio.

Authors:  P Vitish-Sharma; R Shah; M Anjari; J Knowles; K Qurashi
Journal:  BMJ Case Rep       Date:  2012-07-13

3.  Acquired factor VIII inhibitor preceding chronic lymphocytic leukemia.

Authors:  J Mateo; R Martino; M Borrell; M Garí; F Casas; J Fontcuberta
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.